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ABSTRACT: Dried blood spots (DBS) are often used as a less
invasive alternative to venous blood sampling. Despite its numerous
advantages, the use of conventional DBS suﬀers from the hematocrit
(hct) eﬀect when analyzing a subpunch. This eﬀect could be avoided
by using hct-independent sampling devices, of which the hemaPEN
is a recent example. This device collects the blood via four integrated
2.74 μL microcapillaries, each depositing the blood on a prepunched
paper disc. In this study, we evaluated the technical performance of
the hemaPEN devices, using an extensive bioanalytical validation
and application on authentic patient samples. An LC-MS/MS
method quantifying caﬀeine and its metabolite paraxanthine in dried
whole blood (using the hemaPEN device) was fully validated,
meeting all preset acceptance criteria. A comparative analysis of 91
authentic patient samples (hct range: 0.17−0.53) of hemaPEN, 3 mm DBS subpunches, and whole blood revealed a limited hct
dependence (≤7% concentration diﬀerence over a 0.20−0.50 hct range) for the hemaPEN devices, which we could not
attribute to the analytical procedure. Using conventional partial-punch DBS (3 mm punches), concentration diﬀerences of
≥25% over this hct range were found. The hemaPEN showed to be robust to the eﬀects of blood sample volume, device lot,
analytical operator, and storage stability. The technical performance of the hemaPEN when dealing with patients having a high
hct and in cases where a large blood drop is present should be further investigated. Based on the successful validation and
application on patient samples, we conclude that the hemaPEN device shows good potential for the volumetric collection of
DBS.
Microsampling has gained popularity over the past decadebecause of its numerous advantages compared to
conventional venous blood sampling. Many dried blood spot
(DBS)-based methods have been developed for a variety of
applications, e.g., phenotyping, therapeutic drug monitoring,
doping analysis, or toxicology.1−7 A major drawback for
implementing DBS in routine analyses is the presence of a
hematocrit (hct) bias. The origin of this hct-based bias is
threefold.8−10 First, because viscosity of the blood is positively
correlated with the hct, high-hct blood tends to spread less on
ﬁlter paper compared to low-hct blood. As a result, when
applying the same volume onto ﬁlter paper, smaller diameter
spots are generated from higher hct blood compared to low-hct
blood. Consequently, when taking a ﬁxed subpunch of high-hct
DBS, the analyte concentration is typically overestimated
because of the larger volume that is present. This problem is
well-known when using cellulose-based ﬁlter paper. A second
aspect of the hct eﬀect is the fact that it may impact the
extraction eﬃciency and hence the recovery of the analyte.8−11
Generally, a high-hct DBS will form a certain barrier for
extraction, resulting in a lower recovery and underestimation of
the concentration. Third, samples with a diﬀerent hct can be
considered as diﬀerent matrices, possibly causing an hct-
dependent matrix eﬀect.8,9 In the past years, several dried
blood sampling techniques distinct from conventional DBS
collection have been developed such as the Mitra volumetric
absorptive microsampling device (Neoteryx, USA),12,13 the
HemaXis device (DBS system SA, Switserland),14 the
volumetric absorptive paper disc (VAPD), mini-disc (VAPD-
mini),15 and the Capitainer device (KTH, Stockholm,
Sweden).16,17 As most of these allow volumetric collection of
blood, analysis of the complete dried microsample overcomes
the impact of spreading on DBS-based quantitation.8,10 The
recovery and matrix eﬀect can still be inﬂuenced, though.
Optimizing the extraction procedure and chromatographic
conditions are an absolute requirement and therefore need to
be evaluated during method validation.8,10,18 A recent addition
to the panel of alternative devices is the hemaPEN (Trajan,
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Melbourne, Australia), which is based on the volumetric
application of blood onto prepunched ﬁlter paper discs. This
device contains four integrated 2.74 μL microcapillaries, which
are ﬁlled by capillary action when touching a drop of blood. In
a next step, following clicking of the device back into its base,
the capillaries are emptied, depositing the blood onto four
prepunched discs (3.5 mm diameter, PE 226 ﬁlter paper) that
are integrated into the device. A successful proof-of-concept
was already reported by Neto et al.,19 who evaluated the
accuracy and precision using 3 μL end-to-end glass capillaries
in conjunction with prepunched DBS discs. Furthermore, these
results were compared to conventional low-volume blood
collection systems, i.e., a micropipette and a digitally controlled
analytical syringe.19 Both the accuracy and precision of
dispensing a ﬁxed volume onto ﬁlter paper were the same, or
even better, with the capillary method when compared to the
standard methods. In this study, we report the ﬁrst in-depth
evaluation of the technical performance of hemaPEN devices.
This was achieved by an extensive bioanalytical validation and
by application on authentic patient samples, using caﬀeine and
its metabolite paraxanthine as model analytes. These analytes
were chosen as it is easy to collect caﬀeine/paraxanthine
positive samples, within a wide hct range, without the need to
administer a substance. In this way, the accuracy and precision
of the hemaPEN could be determined. A comparative analysis
of hemaPEN DBS, 3 mm DBS subpunches, and whole blood
was conducted to evaluate the hct independence of the
hemaPEN vs. standard DBS technology. This comparison
encompassed the analysis of 91 authentic patient samples with
a broad hct range (0.17−0.53). Additional experiments on a
subset of patient samples were set up to evaluate the
robustness of the hemaPEN to the eﬀects of blood sample
volume, device lot, analytical operator, and storage stability.
Besides evaluation of the analytical performance, we also
evaluated the success rate of the device (i.e., whether all four
capillaries were ﬁlled and dispensed for each sample), based on
the data obtained in the validation and patient study.
■ EXPERIMENTAL SECTION
Chemicals and Stock Solutions. Caﬀeine, paraxanthine,
the internal standards (ISs) caﬀeine-13C3 and paraxanthi-
ne-13C4-
15N3, and formic acid (FA) were purchased from
Sigma-Aldrich (Diegem, Belgium). LC-MS grade methanol
was obtained from Biosolve (Valkenswaard, The Nederlands).
Ultrapure water was produced by a Millipore puriﬁcation
system (Merck Millipore, Overijse, Belgium). A 1 mg/mL
stock solution was prepared for both analytes by dissolving 10
mg of the compound in 10 mL of ultrapure water. For both the
calibrators and QCs, independent 1 mg/mL stock solutions
were made for caﬀeine and paraxanthine, and aliquots were
stored at −20 °C. Working solutions, needed to generate
calibrators and QCs, were freshly made on the day of analysis.
For the IS, a commercial 1 mg/mL solution of caﬀeine-13C3 in
methanol and 2 mg of paraxanthine-13C4-
15N3 was purchased
and diluted to 100 μg/mL in methanol. Aliquots were stored at
−20 °C. This 100 μg/mL stock solution was further diluted on
the day of analysis of DBS to generate a solution in 80:20
MeOH:H2O, containing 0.01% FA, with a concentration of 40
ng/mL caﬀeine-13C3 and 20 ng/mL paraxanthine-
13C4-
15N3.
An aqueous working solution containing 5 μg/mL caﬀei-
ne-13C3 and 2.5 μg/mL paraxanthine-
13C4-
15N3 was prepared
for the analysis of whole blood, as described by De Kesel et
al.20
Sample Collection. The use of blood from healthy
volunteers and of left-over blood samples from patients was
approved by the ethics committee of Ghent University
Hospital (EC2018/0519). Blank venous whole blood was
donated by a healthy female, caﬀeine abstinent donor in EDTA
tubes (BD Vacutainer, New Jersey, USA) to generate
calibrators and QCs on the day of analysis. Venous whole
blood patient samples (EDTA-anticoagulated) were collected
at Ghent University Hospital and were selected across several
hospital departments to cover a wide hct range. HemaPEN
devices were kindly provided by Trajan (Melbourne,
Australia). To generate hemaPEN DBS, 20 μL of venous
whole blood was pipetted onto the top of a 2 mL Eppendorf,
mimicking a drop of blood on a ﬁngertip. The hemaPEN was
then used to sample 4 × 2.74 μL by touching the drop of blood
with the device while holding it horizontally and gently turning
it. This results in ﬁlling of the four 2.74 μL capillaries that are
integrated in the device by capillary action. In a next step, the
hemaPEN is pressed into a base and ﬂipped to allow transfer of
the blood onto four prepunched discs that are also integrated
in the device. After sample collection was completed, the
device was packed again in its original aluminum foil bag and
left at room temperature to dry for at least 2 h. No desiccant
was added during storage, as desiccant is already integrated
into the back of the hemaPEN. In addition, regular DBS were
prepared by pipetting 50 μL of whole blood onto Whatman
903 ﬁlter paper (GE Healthcare, Dassel, Germany). After
drying for minimally 2 h at ambient room temperature, a 3 mm
subpunch was taken for further analysis, which corresponds to
a blood volume of approximately 3.5 μL (the exact volume
contained within this disc depends on the hct). A Sysmex XE-
5000 analyzer (Sysmex Corp., Kobe, Japan), run in manual
mode, was used to determine the hct value of the whole blood,
whenever necessary.
Sample Preparation. For the analysis of venous whole
blood samples, 50 μL of the specimen was transferred into a 2
mL Eppendorf tube. Consequently, 10 μL of an aqueous IS
solution was added followed by the addition of 100 μL of
MeOH/0.01% FA. Samples were subsequently shaken for 10
min at 1000 rpm at 22 °C and centrifuged for 10 min at
10 000g at ambient temperature. In a last step, 40 μL of the
supernatant was transferred to a new 2 mL Eppendorf tube, to
which 130 μL of H2O/0.01% FA was added, prior to the
transfer of 140 μL to a glass vial with a plastic insert. For the
analysis of hemaPEN DBS, a DBS retrieved from a hemaPEN
device was transferred to a 2 mL Eppendorf tube. The analytes
were extracted by adding 50 μL of an 80:20 MeOH:H2O
extraction solvent containing 0.01% FA and the IS.
Subsequently, hemaPEN DBS were shaken for 10 min at
1000 rpm at 60 °C, followed by centrifugation for 10 min at
10 000g at ambient temperature. A 30 μL aliquot of the
supernatant was transferred into a new 2 mL Eppendorf tube,
and 130 μL of H2O/0.01% FA was added. Before analysis, 140
μL was transferred into a glass vial with a plastic insert. For
conventional DBS analysis, 3 mm DBS subpunches were
extracted by adding 70 μL of an 80:20 MeOH:H2O extraction
solvent containing 0.01% FA and the IS, shaking for 10 min at
1000 rpm at 22 °C (or 60 °C, when indicated), and
centrifugating for 10 min at 10 000g at ambient temperature.
To 45 μL of the supernatant, 195 μL of H2O/0.01% FA was
added prior to the transfer of 200 μL into a plastic insert in a
glass vial.
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UHPLC-MS/MS Method. For all samples, 10 μL of extract
was injected onto a Waters Acquity UPLC system (Waters,
Milford, MA, USA), coupled to a SCIEX API 4000 mass
spectrometer (SCIEX, Framingham, MA, USA). Waters
Acquity console software and SCIEX Analyst version 1.6.2
controlled the LC-MS/MS system. Mobile phases A and B
consisted of 0.01% FA in H2O and MeOH, respectively. The
mass spectrometric and chromatographic conditions used for
analysis of the whole blood, hemaPEN, and DBS samples were
identical to those described by De Kesel et al.20
Validation of the hemaPEN Method. The hemaPEN
method validation was based on the European Medicines
Agency (EMA) and U.S. Food and Drug Administration
(FDA) guidelines on bioanalytical method validation,21,22 also
taking into account DBS-speciﬁc parameters, as outlined in the
guideline by Capiau et al.18 The following parameters were
evaluated during method validation: calibration model,
homoscedasticity, accuracy and precision, carry-over, selectiv-
ity, lower limit of quantiﬁcation (LLOQ), stability, matrix
eﬀect, and recovery. The calibration curve, set up in blood with
an hct of 0.41, ranged from 0.1 to 10 μg/mL for caﬀeine and
from 0.05 to 5 μg/mL for paraxanthine. The nominal
concentrations of the calibrators were 0.10, 0.15, 0.20, 0.50,
1.0, 2.0, 5.0, and 10 μg/mL for caﬀeine and 0.050, 0.10, 0.15,
0.20, 0.50, 1.0, 2.0, and 5.0 μg/mL for paraxanthine. The lower
limit of quantiﬁcation (LLOQ) was set at the level of the
lowest calibrator. The low, medium, and high QCs had
concentrations of 0.24/0.12 μg/mL, 2/1 μg/mL, and 8/4 μg/
mL for caﬀeine/paraxanthine, respectively. The most suitable
regression model was determined by calculating the sum
percentage relative error (%RE) for both unweighted and
weighted (1/x, 1/x2, 1/√x, 1/y, 1/y2, and 1/√y) linear and
quadratic regression models. Statistical evaluation to substan-
tiate this choice was done using an R-script developed by
Desharnais et al.23 Using this script, an F-test was performed to
evaluate heteroscedasticity. If weighting was needed, a variance
test for weight selection was done to select the most
appropriate weighting factor. Additionally, a partial F-test
was needed for model order selection. To verify the
prerequisite for this test, a normal distribution of the
standardized residuals, a Cramer von Mises test was
performed. Accuracy and precision were evaluated by the
analysis of four diﬀerent QC levels over 4 diﬀerent days,
analyzed on each day in duplicate. The acceptance criterion for
the %bias was 15%, except for the LLOQ, where it was 20%.
The %coeﬃcient of variation (CV) limit for the repeatability
and total precision was set at 15 and at 20% for the LLOQ.
One-way ANOVA analysis was performed to calculate the
imprecision, as described by Wille et al.24 Carry-over was
assessed by the injection of two blank samples (not containing
analyte or IS in the extraction solvent) after the highest
calibrator and was considered acceptable if the signal was less
than 20% of the LLOQ analyte area and less than 5% of the IS
area. The analysis of seven blank donor samples was used to
evaluate the selectivity. A signal less than 20% of the LLOQ
analyte area and less than 5% of the IS area was required to
conﬁrm the selectivity of the method. Long-term stability (2
months) was assessed at room temperature at low and high
concentration levels (0.12 and 0.06 μg/mL and 8 and 4 μg/mL
for caﬀeine and paraxanthine, respectively). Short-term
stability (4 days) was checked at an elevated temperature of
60 °C at two concentration levels (Low QC and High QC).
The acceptance criterion was less than 15% deviation of the
nominal value. Matrix eﬀect and recovery were assessed as
described by Matuszewski, implying the evaluation of three
sets of samples: one set spiked before extraction, another
spiked after extraction, and a last set in the absence of the
matrix to be assessed.25 In addition to using blank matrices
from seven individual donors (hct = 0.40 to 0.44), one donor
sample was adapted to generate blood at two additional hct
levels (0.20 and 0.58). The matrix eﬀect was assessed at two
diﬀerent concentration levels (Low QC and High QC). The
matrix factor was then calculated for each donor and can be
deﬁned as the ratio of the analyte peak area in the presence of
matrix to the peak area in the absence of that same matrix.
Also, the IS-normalized matrix eﬀect was calculated by
including the IS areas in the presence and absence of the
matrix in the matrix factor. The EMA guidelines on
bioanalytical method validation state that the CV (%) on the
IS-normalized matrix factor, calculated from the seven lots of
matrix and two adapted hct matrices, should not exceed 15%.
To evaluate the recovery and a possible impact of the hct on
the recovery, two sets of blood samples (n = 6) were prepared
at three diﬀerent hct levels (0.21, 0.41, 0.60). A ﬁrst set, prior
to hemaPEN sampling and extraction, was spiked with analyte
at two diﬀerent concentration levels (Low QC and High QC).
The second set was used for the hemaPEN-assisted collection
of blank DBS, which were extracted using IS-containing
extraction solvent and spiked with the theoretical amount of
analyte present in 2.74 μL of blood. Recovery (expressed as a
%) was calculated by dividing the peak areas at each condition
in the set spiked before extraction by those of the
corresponding samples spiked after extraction. The recoveries
for the low- and high-hct blood were expressed relative to the
extraction recovery for 0.41 hct blood. The recovery was
considered hct-independent when the relative IS-compensated
recovery for both low- and high-hct DBS was within ±15% of
the recovery for DBS with a 0.41 hct.
Application. A comparative study was conducted to
compare caﬀeine and paraxanthine concentrations between
hemaPEN DBS, 3 mm subpunches from DBS collected on
Whatman 903 ﬁlter paper, and liquid whole blood. Left-over
EDTA whole blood samples from hospital patients, preselected
to ensure an even distribution in a wide hct range, were
analyzed in duplicate to select caﬀeine and paraxanthine
double positive samples (above the LLOQ for both analytes; n
= 96). Analysis was performed based on a previously published
method.20 Only positive samples for which the two whole
blood measurements did not diﬀer by more than 20% were
included in the data set (for caﬀeine seven samples and for
paraxanthine four samples were excluded based on the whole
blood measurements). As an additional quality check for all
analyses of the patient samples, in all instances, the
paraxanthine to caﬀeine ratio was determined and compared
to this ratio in liquid whole blood. Irrespective of the matrix
used for analysis, this ratio should remain the same for a given
sample. A generalized ESD test revealed one outlier (a
conventional DBS sample), leading to the exclusion of this
patient sample. This yielded an eventual data set of 88 samples
for caﬀeine and 91 samples for paraxanthine. All positive
samples were used for the generation of DBS using the
hemaPEN and by pipetting 50 μL of blood onto Whatman 903
ﬁlter paper to prepare regular DBS. Likewise, calibrators and
QCs were generated using the hemaPEN or by pipetting blood
onto ﬁlter paper. The use of isolated 2.74 μL capillaries (as
present in the hemaPEN) to manually prepare calibrators and
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QCs was considered and tried but was not practical and
therefore not considered further. Since four DBS are generated
per hemaPEN, incurred sample reanalysis could be performed
by analyzing a second and third spot of the same device for
each patient sample. Both incurred sample reanalyses were
compared to the original hemaPEN analysis for both analytes
by calculating the % diﬀerence as (incurred sample reanalysis
− hemaPEN DBS original measurement)/(mean of both
analyses). At least two-thirds of the results should be within
20%. This % deviation was plotted against sample number
according to increasing analyte concentration. The eﬀect of the
hct on the determination of caﬀeine and paraxanthine using
the hemaPEN was assessed by plotting the % diﬀerence with
whole blood as a function of the hct. The % diﬀerence was
calculated as the (hemaPEN DBS concentration − whole
blood concentration)/whole blood concentration. The same
plot was made for the 3 mm DBS subpunch to conﬁrm the hct
eﬀect that should be present when using a DBS subpunch.13,16
In another set of patient samples with either low or high hct,
the caﬀeine and paraxanthine concentrations, determined after
full-spot analysis of DBS that were generated by pipetting 2.74
μL onto 3 mm prepunched ﬁlter paper discs (analyzed in
triplicate), were compared with those from corresponding
whole blood (analyzed in duplicate). The % diﬀerence was
calculated as [full DBS concentration (mean of triplicates) −
whole blood concentration (mean of duplicates)]/mean whole
blood concentration and was plotted against the hct. Linear
regression analysis was performed to identify a possible trend
of the % diﬀerence (hemaPEN DBS vs. whole blood or
pipetted DBS vs. whole blood) as a function of the hct.
Subsequently, the concordance between whole blood concen-
trations and hemaPEN DBS concentrations was investigated
by Bland−Altman plots where the diﬀerence of both
measurements divided by the mean (expressed as a %) was
plotted against the mean of both measurements. This allows a
conclusion to be made if there is an overall over- or
underestimation of the concentration obtained from the
hemaPEN DBS compared to that in whole blood. Medcalc
statistical software, version 14.12.0, was used to create Bland−
Altman plots.
The hemaPEN robustness to the eﬀects of blood sample
volume, device lot, analytical operator, and storage stability was
evaluated using a subset (n = 25) of the caﬀeine/paraxanthine
positive patient samples, carefully selected to ensure a spread
across the entire available hct range (0.17 to 0.57). The impact
of blood volume was assessed by depositing 50 μL (instead of
20 μL) of blood onto an Eppendorf cap to generate DBS using
the hemaPEN. These two volumes were chosen as the
minimum volume required to easily ﬁll the four capillaries,
which will in practice be close to 20 μL, whereas a 50 μL blood
drop lying on top of a ﬁngertip can be considered already quite
large. Alternatively, hemaPEN devices of another lot or
hemaPEN devices of the same lot but handled by another
operator were used. Two-thirds of the results should not vary
by more than 20% of the mean of both concentrations (i.e.,
mean of original hemaPEN measurement and altered
parameter measurement). The % diﬀerence is calculated as
(altered parameter hemaPEN concentration − original
hemaPEN concentration)/mean of both concentrations.
Stability and the absence of extractability issues when working
with authentic samples was assessed by storing hemaPEN
devices for 4 days at 60 °C after drying at room temperature.
Here, the mean deviation between the result and original
concentration should not diﬀer more than 15%. This was
calculated as (concentration after 4 days at 60 °C − original
concentration)/original concentration. For the evaluation of all
parameters related to hemaPEN robustness, analyses were
performed in singlicate.
Additionally, a small transport simulation study was
performed. Fingerstick samples were collected from 10
volunteers, using 2 hemaPEN devices, to prepare 2 sets of
samples. Each volunteer provided a written informed consent
(cfr. EC2018/0519). The ﬁngerstick was performed using a
BD microtainer contact-activated safety lancet (BD, Franklin
Lakes, USA). One set of hemaPEN devices was retained in the
laboratory, and the other replicate was posted from a nearby
post oﬃce to the laboratory. In this way, transport and
exposure to “real” environmental conditions were simulated.
Per hemaPEN, two replicate spots were analyzed in the same
batch against a freshly extracted calibration curve. Two-thirds
of the results of the laboratory and transported samples must
not vary by more than 20%.
As the hemaPEN contains four 2.74 μL capillaries that
should each transfer blood onto the prepunched paper discs in
the cartridge inside the pen, the success rate of ﬁlling and
emptying of all capillaries was another parameter that could be
assessed. For all samples (calibrators, QCs, and patient
samples), the hemaPEN ID, the hct of the blood, the number
of capillaries ﬁlled with blood during sampling, and the number
of capillaries where an actual transfer of blood took place were
recorded. This allowed insight into the parameters aﬀecting the
functionality of the hemaPEN device.
■ RESULTS AND DISCUSSION
Method Validation. Calibration data from the four
validation days (n = 8) were plotted. Homoscedasticity was
determined by performing an F-test. As the calibration data
were heteroscedastic, weighting was required, with 1/x2
weighting being chosen based on the lowest sum %RE.
Using 1/x2 linear models, the back-calculated concentrations
were within 15% (with a single exception) for all calibrators for
both analytes, justifying the use of this model. Statistical
evaluation, using an R-script developed by Desharnais et al.,23
substantiated this choice. For both analytes, a bias smaller than
6% was found at all concentration levels, as shown in Table 1.
Both analytes could be determined in hemaPEN DBS with a
Table 1. Within Day and Total Precision and Accuracy (n = 4 × 2) for QCs of Caﬀeine and Paraxanthine at Four
Concentration Levels (LLOQ, low, mid, and high) in hemaPEN.
within day precision (%CV) (n = 4 × 2) total precision (%CV) (n = 4 × 2) accuracy (%bias) (n = 4 × 2)
QC caﬀeine paraxanthine caﬀeine paraxanthine caﬀeine paraxanthine
LLOQ 7.59 5.50 8.96 10.20 3.48 −0.82
Low QC 7.64 3.49 8.14 8.51 0.36 3.54
Mid QC 3.46 5.08 8.26 7.16 −5.38 −4.21
High QC 3.53 3.11 6.19 3.28 −0.61 1.47
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repeatability below 8% (CV%) and a total imprecision below
11% (CV%). Selectivity and carry-over were within the preset
limits (<20% of the LLOQ area and <5% of the IS area).
Absolute recovery was, for both analytes at each hct level,
higher than 86%. IS-compensated recovery ranged between 98
and 122%. CV’s on the IS-compensated recovery were below
9% and therefore within the preset acceptance criterion of
15%. The recovery was hct-independent (i.e., within ±15% of
the recovery for hemaPEN DBS with a 0.41 hct), as depicted
in Figure 1, although for the caﬀeine low QC, a statistically
signiﬁcant eﬀect (p < 0.05) of the hct on the recovery was
found. Post hoc analysis revealed a signiﬁcant diﬀerence
between the recovery for 0.60 hct DBS and both 0.41 and 0.21
hct DBS. Analyte matrix eﬀects were for both analytes within
94−105%, as shown in the Supplementary Data (Suppl. Data
Table S-1). IS-compensated matrix eﬀects were within 99−
104%, with CV’s below 6%, thus amply meeting the preset
acceptance criterion of 15%.
Both caﬀeine and paraxanthine were stable (i.e., within
11.5% of the nominal concentration) for at least 2 months at
room temperature and 4 days at 60 °C when storing the
hemaPEN devices in their original packages (Suppl. Data
Table S-2). From these stability experiments, it can also be
concluded that there are no “extractability” issues, when
comparing very dry and freshly dried DBS. From all the above-
mentioned experiments, it can be concluded that the analytical
validation of the hemaPEN, with inclusion of hct as an
additionally evaluated parameter, was successful.
Application. Caﬀeine and paraxanthine were determined
in duplicate (in independent runs) in venous whole blood
patient samples (hct range = 0.17−0.53; median = 0.345),
hemaPEN DBS, and 3 mm partial-punch DBS. For both
analytes (n = 88 for caﬀeine and n = 91 for paraxanthine), the
mean of the duplicate whole blood measurements was deﬁned
as the reference concentration. Since four DBS spots are
generated per hemaPEN, incurred sample reanalysis could be
performed by analyzing a second and third spot of the same
device for each patient sample. Both incurred sample
reanalyses were compared to the original hemaPEN analysis
for both analytes. As shown in Figure 2, for both caﬀeine and
paraxanthine, the acceptance criterion of two-thirds of the
concentrations having a diﬀerence of less than 20% was met.21
For the ﬁrst incurred reanalysis, 99% of the results for both
analytes had a diﬀerence less than 20%. For the second
reanalysis, 92% of the caﬀeine concentrations and 85% of the
paraxanthine concentrations diﬀered less than 20% from the
original hemaPEN measurement. An overall negative bias for
the ﬁrst reanalysis and positive bias for the second reanalysis
could be explained by a slightly deviating calibration bias.
The concordance between hemaPEN DBS concentrations
(mean of three analyses) and whole blood concentrations
(mean of two analyses) for both analytes is depicted by the
Bland−Altman plots in Figure 3. For caﬀeine, an overall
concentration diﬀerence of −5.6% between whole blood and
hemaPEN DBS was found, implying a slight underestimation
of the hemaPEN DBS concentration compared to whole
blood. For paraxanthine, a similar diﬀerence of −4.4% was
found. This concentration diﬀerence may be ascribed to a
slight diﬀerence in calibration, since daily prepared calibration
curves were used, and analyses were performed on diﬀerent
days. All mean hemaPEN DBS measurements diﬀered less than
20% from the whole blood concentration for caﬀeine and for
paraxanthine. The Bland−Altman comparison for whole liquid
blood to 3 mm partial-punch DBS can be found in the
supplementary data (Suppl. Data Figure S-1).
Furthermore, the concentration diﬀerences between 3 mm
partial-punch DBS and whole blood and hemaPEN DBS vs.
whole blood were plotted against the hct, as shown in Figure 4.
In line with earlier observations,13,16 we found a pronounced
hct bias when using subpunches of regular DBS (Figure 4A,D).
When performing linear regression analysis to describe the %
concentration diﬀerence as a function of the hct, the slope of
the regression line did not include zero for both caﬀeine and
paraxanthine, indicating a signiﬁcant hct eﬀect. When
evaluating what impact is imposed by the hct when comparing
a sample with an hct of 0.20 vs. a sample with an hct of 0.50,
this implies concentration diﬀerences of 25.7 and 26.3%, for
caﬀeine and paraxanthine, respectively. Previously, we already
demonstrated that our extraction procedure for conventional
Figure 1. IS-compensated recovery (%) of caﬀeine (CAF) and
paraxanthine (PRX) for hemaPEN DBS, measured at two
concentration levels for diﬀerent hct levels (0.21; 0.41; 0.60) (n =
5 or 6) and relative to the recovery of a DBS with 0.41 hct. For the
CAF Low QC spiked before extraction set, two outliers could be
identiﬁed with a Dixon Q-test (n = 5 for the calculation of the IS-
normalized recovery factor for Low QC at hct of 0.21 and 0.41). This
was probably due to external contamination of the sample since only
caﬀeine areas deviated. * indicates a statistically signiﬁcant diﬀerence
(two-sided ANOVA; p < 0.05).
Figure 2. First and second incurred sample reanalyses compared to
the original hemaPEN measurement for caﬀeine (A) and paraxanthine
(B) in % diﬀerence. The numbering of the x-axis refers to the number
of samples, ranked here based on increasing concentration.
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DBS was hct-independent, so this eﬀect can be related to the
spreading eﬀect of the hct, rather than to an hct-imposed
extractability issue.13,20 Yet, as we previously demonstrated
that extraction at higher temperatures may overcome
extractability issues,13,26 we repeated the analysis, using
replicates of the partial-punch DBS that were extracted at 60
°C instead of at 22 °C. Still, diﬀerences exceeding 25% were
observed, thus excluding that hct-imposed extractability issues
would play a role in this observation. When plotting the
concentration diﬀerences between hemaPEN DBS versus
whole blood, expressed as a %, versus the hct, concentration
diﬀerences of 10.2 and 5.7% were obtained when comparing a
sample with an hct of 0.20 vs. 0.50 (Suppl. Data Figure S-2).
Although this is much less than the eﬀect observed for
conventional DBS, we were surprised to ﬁnd any impact of the
hct. Statistical analysis demonstrated that the observed
diﬀerences, though limited, were signiﬁcant, as evidenced by
the fact that the slope of the regression line was signiﬁcantly
diﬀerent from zero. This unexpected ﬁnding was conﬁrmed for
both analytes by plotting in a similar manner the regression
lines for the incurred hemaPEN DBS reanalyses: in both
reanalyses and for both analytes, zero was not included in the
95% conﬁdence interval of the slope (Suppl. Data Figure S-2).
When considering samples with an hct of 0.20 vs. 0.50, the
% diﬀerence between the mean of the three hemaPEN DBS
concentrations and those in whole blood was 6.90% for
caﬀeine and 5.40% for paraxanthine (Figure 4B,E). From
Figure 4, it is also clear that, although the impact of the hct
reaches statistical signiﬁcance, it is overall quite limited,
certainly when comparing hemaPEN results with conventional
partial-punch DBS results. Moreover, when considering the
impact relative to an intermediate hct (0.40), the impact for
the entire evaluated range (0.17−0.53) remained within 6%,
which can be considered negligible.
As we considered it remarkable that, when using the
hemaPEN device to generate DBS from blood with a lower
hct, concentrations appeared to be slightly underestimated, we
performed an additional experiment. This experiment,
performed on an independent set of patient samples, involved
full-spot analysis of DBS that were generated by pipetting 2.74
μL of patient blood samples with either low or high hct values
on prepunched 3 mm Whatman 903 ﬁlter paper discs
(analyzed in triplicate) and comparison of the obtained results
with those of the corresponding whole blood samples
(analyzed in duplicate). For caﬀeine, 15 samples with an hct
below 0.29 and 27 with an hct above 0.45 were included. For
paraxanthine, 15 samples with an hct below 0.29 and 24 with
Figure 3. Bland−Altman plots for the comparison between whole
blood and mean hemaPEN concentrations for caﬀeine (n = 88) and
paraxanthine (n = 91). Mean diﬀerences and limits of agreement
(LoA) are represented by full lines, and 95% conﬁdence limits are
represented by broken lines.
Figure 4. % diﬀerence between 3 mm partial-punch DBS, hemaPEN DBS, or full 2.74 μL DBS and whole blood concentrations, plotted against hct
for caﬀeine (in panels A, B, and C respectively) and paraxanthine (in panels D, E, and F respectively). Broken lines represent linear regression lines.
The respective slopes for 3 mm partial-punch DBS, hemaPEN DBS, and full-spot DBS were 0.0089 (95%CI [0.006848; 00.010986]), 0.0023 (95%
CI [0.00122; 0.00344]), and 0.0013 (95%CI [−0.00012; 0.00268]) for caﬀeine and 0.0086 (95%CI [0.00630; 0.01082]), 0.0018 (95%CI
[0.00075; 0.00275]), and 0.0013 (95%CI [−0.000068; 0.002623]) for paraxanthine. The respective intercepts for 3 mm partial-punch DBS,
hemaPEN DBS, and full-spot DBS were −0.4995 (95%CI [−0.5728; −0.4262]), −0.1324 (95%CI [−0.1717; −0.0931]), and −0.0496 (95%CI
[−0.1072; 0.0081]) for caﬀeine and −0.4137 (95%CI [−0.4938; −0.3335]), −0.1018 (95%CI [−0.1373; −0.0663]), and −0.0277 (95%CI
[−0.0824; 0.0269]) for paraxanthine.
Analytical Chemistry Article
DOI: 10.1021/acs.analchem.9b03179
Anal. Chem. 2019, 91, 14467−14475
14472
an hct above 0.45 were included. One data point was excluded,
because the CV of the triplicate analysis of a full DBS exceeded
15% for both analytes, indicating a technical issue. Based on a
generalized ESD test, one full-spot DBS sample was excluded
because of a deviating paraxanthine to caﬀeine ratio. The %
diﬀerence was calculated as (mean DBS concentration − mean
whole blood concentration)/mean whole blood concentration
and was plotted against the hct. Linear regression analysis did
not reveal a signiﬁcant trend as a function of the hct for both
analytes, as zero was included in the 95% CI of both slopes, as
depicted in Figure 4C,F. Re-evaluation of the hemaPEN−
whole blood comparison, only taking into account the samples
with hct values below 0.29 and above 0.45 still yielded a
signiﬁcant trend. Based on the results of the additional
experiment including full-spot analysis of volumetrically
applied DBS, it cannot be stated that the small hct bias
observed for the hemaPEN devices is related to the analytical
procedure. As in the case of blood with low hct, the capillaries
are not only ﬁlled but also emptied faster,19,27 we hypothesize
that this quick emptying might result in somewhat more
retention of liquid in the capillaries.
In a second set of experiments, we evaluated the robustness
of the hemaPEN to the eﬀects of blood sample volume, device
lot, analytical operator, and storage stability. A subset of 25
patient samples, with an hct ranging from 0.17 to 0.57, was
used for this purpose. When presenting 50 μL instead of 20 μL
blood drops to the hemaPEN, 92 and 87% of the caﬀeine and
paraxanthine concentrations diﬀered less than 20%, thereby
complying with the preset criterion of 67%. When using
another lot of hemaPENs, all results lay within 20% of those
obtained using the ﬁrst hemaPEN lot. Respectively, 8 and 20%
of the caﬀeine and paraxanthine samples sampled by another
operator showed a % diﬀerence with the ﬁrst operator above
20%. Hence, also here the preset acceptance criterion was met.
In supplementary data (Suppl. Data Figure S-3), the %
diﬀerences for all these subsets are depicted. Mean diﬀerences
compared to the original were 4, 2, and 8% for the 50 μL,
another batch, and other operator sets respectively, for caﬀeine
and 8, 6, and 13% for paraxanthine. To also evaluate sample
stability in and extractability from authentic patient samples,
rather than solely in spiked QCs, the stability of caﬀeine and
paraxanthine in hemaPEN devices, used to generate DBS from
the aforementioned 25 patient samples, was assessed after
storage for 4 days at 60 °C. When compared to the original
hemaPEN concentrations, a mean deviation of 0.3% for
caﬀeine and of 8% for paraxanthine was found, meeting the
preset acceptance criterion of ±15% and conﬁrming that there
is neither a stability nor an extractability issue (Suppl. Data
Figure S-3).
Samples from 10 volunteers who conﬁrmed not to be
caﬀeine abstinent were included in a transport simulation
study. All volunteers received a brief description about usage of
the device; 3/10 had used the device before. For 6/10
volunteers, duplicate samples for both hemaPENs could be
obtained. For two volunteers, the hemaPEN that stayed in the
laboratory contained only one DBS. For the remaining two
volunteers, sampling with one pen failed, and as a
consequence, no comparison could be made. Hence, data
from eight diﬀerent volunteers were included in data analysis.
When a duplicate sample was available in the pen that stayed in
the lab, the mean was calculated and considered as the
reference concentration. In the two cases where only a single
sample was available, this was considered the reference.
For each volunteer, the % diﬀerence between the hemaPEN
DBS concentration of the pen that stayed in the lab and that of
the hemaPEN DBS after transport is depicted in Figure 5. In
all but one case (sample 8a), the deviation was less than 20%.
We have no clear-cut explanation for the deviating result that
suggests overﬁlling of a DBS, especially as in a replicate from
the same hemaPEN (sample 8b) for both analytes, the
diﬀerence from the reference concentrations was less than
2.5%. The median absolute deviation was 5% for both analytes.
Last, in addition to the analytical performance, we also
assessed the success rate (technical performance) of the
hemaPENs that had been used for the validation (calibrators
and QCs) and for the patient sample study. Both the ﬁlling and
the emptying of all four capillaries were scored. In Figure 6, the
number of capillaries transferred is plotted as a function of the
hct (ﬁlling had for all the venous samples a 100% success rate).
For 20 μL blood samples with an hct above 0.50, we observed
an increased failure rate in emptying of the capillaries: for 12/
23 samples with an hct above 0.50, less than 4 spots were
generated from completely ﬁlled capillaries, which contrasts
with only 6 out of 246 samples with an hct below 0.50 for
which less than 4 spots were obtained. This might be relevant
for pediatric populations, since for this population, the use of
microsampling is a substantial advantage, and hct values are
generally higher, values above 0.50 not being exceptional. As in
this study the share of samples with a high hct (above 0.50)
was limited (n = 23), further research is warranted to
determine to what extent this poses a true problem.
Figure 5. Deviation (%) between the caﬀeine and paraxanthine
concentrations determined after transport vs. the concentrations
determined in the hemaPEN DBS that stayed in the lab, which are
considered as the reference.
Figure 6. hemaPEN functionality expressed as the number of
capillaries transferred onto the DBS prepunch in function of the hct of
the venous blood sample.
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Also, for the set of 25 samples where 50 μL of blood was
presented to the hemaPEN (Figure 6, triangles), transfer onto
the prepunched disc seemed to be less eﬃcient (in 13 cases, no
successful generation of four DBS), although also here the
sample size was limited. This might be due to an excess of
blood clogging the capillary inlet, thereby inhibiting capillary
action to take place. Following clicking the hemaPEN in its
base, capillary action is the driving force for the transfer of the
ﬁlled capillaries onto the prepunched ﬁlter paper discs inside
the hemaPEN. Obviously, in a home sampling scenario, blood
will not be pipetted into an Eppendorf to sample blood with a
hemaPEN device but will be obtained from a ﬁngerstick. In
this scenario, clogging of the capillaries could also take place
when a blood drop is generated that is too large. The
functionality when dealing with patients having a high hct and
in cases where a large blood drop is present should further be
investigatedhowever, this was not among the aims of our
study. Anyway, to guarantee the successful generation of DBS
using the hemaPEN, we feel that training of patients or
caregivers involved with this sampling technique will be an
essential element. On the other hand, the hemaPEN
automatically generates four replicate spots in one pen. In
this study, in only a few cases, none (one case) or only one
(four cases) out of the four samples could be generated.
Therefore, sample analysis will in the far majority of the cases
still be possible, even with high-hct samples or when large
volumes of blood are in contact with the capillary inlet.
■ CONCLUSION
An LC-MS/MS method for the determination of caﬀeine and
its metabolite paraxanthine in DBS generated using hemaPEN
devices was successfully validated based on the European
Medicines Agency (EMA) and U.S. Food and Drug
Administration (FDA) guidelines on bioanalytical method
validation.21,22 Since all preset acceptance criteria were met, it
can be concluded that these devices allow the accurate and
precise collection of a ﬁxed amount (2.74 μL) of blood. The
hemaPEN device was proposed as an alternative, volumetric,
hct-independent DBS device.19 The potential of these devices
to cope with the hct-based bias, seen in regular subpunched
DBS, was evaluated by analyzing 88 and 91 authentic patient
samples (hct range 0.17 to 0.53) for caﬀeine and paraxanthine.
The comparison of analyte concentrations measured in
hemaPEN DBS with those in liquid venous whole blood
samples revealed a slight (but statistically signiﬁcant) hct-based
bias (6.90 and 5.40% concentration diﬀerences for caﬀeine and
paraxanthine, respectively, over a 0.20−0.50 hct range). This
eﬀect, which we could not attribute to the analytical procedure,
is very limited when compared to subpunched DBS, showing
concentration diﬀerences with whole blood of ≥25% over this
hct range. Moreover, when considering the impact relative to
an intermediate hct (0.40), the impact remained within 6% for
the entire evaluated hct range (0.17−0.53) and may be
considered negligible. Evaluation of the hemaPEN robustness
to the eﬀects of blood sample volume, device lot, analytical
operator, and storage stability passed the preset criteria for all
of the above-mentioned variables. Furthermore, transport of
eight capillary samples from eight healthy volunteers by postal
services revealed no instability of both analytes. The technical
performance of the hemaPEN when dealing with patients
having a high hct and in cases where a large blood drop is
present should be further investigated. Based on all the above
ﬁndings, the hemaPEN device shows good potential as an
alternative for conventional DBS, being an almost hct-
independent microsampling device, allowing volumetric
collection of DBS. Further evaluation using true capillary
blood samples obtained by ﬁngerstick is warranted to further
evaluate the performance of the device under realistic
circumstances.
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